COMMUNIQUÉS West-GlobeNewswire

WeightWatchers for Business Annual Report Shows Breakthrough Weight Loss Results and Health Outcomes
15/10/2025
Members See 46% Improvement in Work-Related Quality of Life and 53% Improvement in Overall Quality of Life WeightWatchers Members Lost 21% of Their Body Weight, Outperforming Results by Other Telehealth Providers NEW [...]
Ketabon Presents New Data Showing Antidepressant Effects of Oral Ketamine (KET01) Are Independent of Dissociation
15/10/2025
Findings Presented at ECNP 2025 in Amsterdam Support the Potential for a Safe At-Home Treatment Option in Treatment-Resistant Depression MUNICH, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company [...]
Eascra Biotech Named to Fast Company’s “Next Big Things in Tech 2025”
15/10/2025
Recognition for groundbreaking work and pioneering space manufacturing BOSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Fast Company has named Eascra Biotech, a nanomedicine startup, to its annual Next Big Things in Tech list [...]
Consortium consisting of Nordic Capital and Permira increases offer price and extends offer period until 5 November 2025 in respect of the takeover offer to the shareholders of Bavarian Nordic
15/10/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 41 - 2025
15/10/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 06 Octobre au 10 Octobre 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 41 - 2025
15/10/2025
Aggregated presentation by day and by market Statement of transactions in own shares from October 06th to October 10th 2025 Name of the issue Identity code of the issuer (Legal Entity Identifier) Day of the transaction [...]
HC3 Named Exclusive U.S. Distributor of MICA Advance System for Rapid Legionella Detection
15/10/2025
Tallahassee, Florida, Oct. 15, 2025 (GLOBE NEWSWIRE) -- HC3 Health Care Consulting has officially been named the exclusive U.S. distributor and training provider for the MICA Advance Legionella system , a next- [...]
EssilorLuxottica acquiert RetinAI, accélérant dans les solutions transformatrices de santé de l’œil portées par l'IA et la data
15/10/2025
EssilorLuxottica acquiert RetinAI, accélérant dans les solutions transformatrices de santé de l’œil portées par l'IA et la data Paris, France (15 octobre 2025) – EssilorLuxottica annonce l'acquisition d'Ikerian AG, une [...]
EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutions
15/10/2025
EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutions Paris, France (15 October 2025) – EssilorLuxottica announces the acquisition of Ikerian AG, a health technology [...]
OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025
15/10/2025
OSE Immunotherapeutics publie ses résultats financiers du 1 er semestre 2025 Nantes, France, le 15 octobre 2025, 19 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , publie aujourd’hui ses résultats [...]
OSE Immunotherapeutics Reports First Half 2025 Financial Results
15/10/2025
OSE Immunotherapeutics Reports First Half 2025 Financial Results NANTES, France, October 15, 2025 – 7:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today reported its consolidated financial [...]
Rezolute to Participate in Upcoming Investor Conferences
15/10/2025
REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today [...]
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
15/10/2025
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report [...]
Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25
15/10/2025
OAK RIDGE, Tenn., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the MedAxiom Cardiovascular (CV) [...]
Step Pharma announces completion of €38 million Series C financing
15/10/2025
Financing will support the Company’s ongoing clinical development of its lead asset, dencatistat, across multiple indications Round led by new investor V-Bio Ventures, with participation from existing investors Pontifax [...]
Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors
15/10/2025
Seasoned clinician and R&D leader brings extensive experience in translational medicine, drug development, and infectious disease research WESTLAKE VILLAGE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Turn [...]
Extendicare Announces October 2025 Dividend of C$0.042 per Share
15/10/2025
MARKHAM, Ontario, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of [...]
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
15/10/2025
NMPA’s response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug [...]
Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio
15/10/2025
Collaboration and license agreement will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with a new asset expected to enter first-in-human studies next year . New, potentially best-in-class ADC is [...]

Pages